All Stories

  1. Examining hypoglycemia risk with systemic fluoroquinolone use: A systematic review and meta-analysis

    Article • CMI Communications, December 2024, Elsevier

    Dr. JM Gamble

  2. Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?

    Article • Diabetes Obesity and Metabolism, January 2024, Wiley

    Dr. JM Gamble

  3. Insulin, hypoglycaemia and dementia: A causal mediation analysis showcasing challenges and potential opportunities

    Article • Diabetes Obesity and Metabolism, November 2023, Wiley

    Dr. JM Gamble

  4. Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom

    Article • Diabetes Obesity and Metabolism, August 2023, Wiley

    Dr. Wasem Alsabbagh, Dr. JM Gamble

  5. Insulin Use in Type 2 Diabetes and the Risk of Dementia: A Comparative Population-Based Cohort Study

    Article • Diabetes Care, June 2023, American Diabetes Association

    Dr. JM Gamble

  6. Author’s Reply to Kuss and Rathmann’s Comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data”

    Article • Drug Safety, April 2023, Springer Science + Business Media

    Dr. JM Gamble

  7. Trends in estimated total retail dispensed prescriptions of purported COVID-19 treatments and preventions in Canada

    Article • Journal of Pharmaceutical Health Services Research, April 2023, Oxford University Press (OUP)

    Dr. JM Gamble

  8. Prescribing Trends of the Sodium–Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015–2021)

    Article • Canadian Journal of Diabetes, March 2023, Elsevier

    Dr. JM Gamble

  9. Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap

    Article • December 2022, Springer Science + Business Media

    Dr. JM Gamble

  10. Associations of Mid- and Late-Life Severe Hypoglycemic Episodes With Incident Dementia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study

    Article • Diabetes Care, December 2022, American Diabetes Association

    Dr. JM Gamble

  11. Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling

    Article • International Journal of Epidemiology, September 2022, Oxford University Press (OUP)

    Dr. JM Gamble

  12. Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.”

    Article • Drug Safety, June 2022, Springer Science + Business Media

    Dr. JM Gamble

  13. Peak performance: Putting type 1 diabetes management recommendations for athletes to the test

    Article • American Journal of Medicine Open, June 2022, Elsevier

    Dr. JM Gamble

  14. Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus

    Article • Diabetic Medicine, May 2022, Wiley

    Dr. JM Gamble, Dr. Wasem Alsabbagh

  15. Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, May 2022, Taylor & Francis

    Dr. JM Gamble

  16. Variation in bleeding risk estimates among online calculators

    Article • Canadian Family Physician, April 2022, The College of Family Physicians of Canada

    Dr. JM Gamble

  17. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs

    Article • Diabetes & Metabolism, March 2022, Elsevier

    Dr. Wasem Alsabbagh, Dr. JM Gamble

  18. Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data

    Article • Drug Safety, March 2022, Springer Science + Business Media

    Dr. JM Gamble

  19. Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors

    Article • British Journal of Clinical Pharmacology, February 2022, Wiley

    Dr. JM Gamble

  20. Sodium-glucose cotransporter-2 inhibitors and urinary tract infections: A propensity score matched population-based cohort study.

    Article • Canadian Journal of Diabetes, December 2021, Elsevier

    Dr. Wasem Alsabbagh, Dr. JM Gamble

  21. Trends and Determinants of Self-Reported Aspirin Use among Patients with Diabetes Stratified by the Presence and Risk of Cardiovascular Diseases - Repeated Pan-Canadian Cross-Sectional Study

    Article • Canadian Journal of Diabetes, December 2021, Elsevier

    Dr. Wasem Alsabbagh, Dr. JM Gamble

  22. Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study

    Article • BMJ Open Diabetes Research & Care, December 2021, BMJ

    Dr. JM Gamble

  23. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date

    Article • Drug Design Development and Therapy, July 2021, Taylor & Francis

    Dr. JM Gamble

  24. Variation and appropriateness of antipsychotic use in long-term care facilities across Newfoundland and Labrador

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, April 2021, SAGE Publications

    Dr. JM Gamble

  25. Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events

    Article • American Journal of Epidemiology, March 2021, Oxford University Press (OUP)

    Dr. JM Gamble

  26. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews

    Article • Therapeutic Advances in Drug Safety, January 2021, SAGE Publications

    Dr. JM Gamble

  27. Gender Differences in Inhaled Pharmacotherapy Utilization in Patients with Obstructive Airway Diseases (OADs): A Population-Based Study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, September 2020, Taylor & Francis

    Dr. JM Gamble

  28. Perceptions of Patients Regarding Mobile Health Interventions for the Management of Chronic Obstructive Pulmonary Disease: Mixed Methods Study

    Article • JMIR mhealth and uhealth, July 2020, JMIR Publications Inc.

    Dr. JM Gamble

  29. The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews

    Article • Endocrinology Diabetes & Metabolism, May 2020, Wiley

    Wajd alkabbani, Dr. JM Gamble

  30. Too young for Cannabis? Choice of minimum legal age for legalized non-medical Cannabis in Canada

    Article • BMC Public Health, May 2020, Springer Science + Business Media

    Dr. JM Gamble

  31. Thiazide Diuretic–Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials

    Article • Journal of General Internal Medicine, March 2020, Springer Science + Business Media

    Dr. JM Gamble

  32. Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment

    Article • Canadian Journal of Diabetes, February 2020, Elsevier

    Dr. JM Gamble

  33. Features of a mobile health intervention to manage chronic obstructive pulmonary disease: a qualitative study

    Article • Therapeutic Advances in Respiratory Disease, January 2020, SAGE Publications

    Dr. JM Gamble

  34. Perceptions of Patients Regarding Mobile Health Interventions for the Management of Chronic Obstructive Pulmonary Disease: Mixed Methods Study (Preprint)

    Article • December 2019, JMIR Publications Inc.

    Dr. JM Gamble

  35. Comparative Safety and Effectiveness of Inhaled Bronchodilators and Corticosteroids for treating Asthma-COPD Overlap: A Systematic Review and Meta-Analysis

    Article • Journal of Asthma, October 2019, Taylor & Francis

    Dr. JM Gamble

  36. Perceptions of Health Care Providers Regarding a Mobile Health Intervention to Manage Chronic Obstructive Pulmonary Disease: Qualitative Study

    Article • JMIR mhealth and uhealth, June 2019, JMIR Publications Inc.

    Dr. JM Gamble

  37. Perceptions of Health Care Providers Regarding a Mobile Health Intervention to Manage Chronic Obstructive Pulmonary Disease: Qualitative Study (Preprint)

    Article • March 2019, JMIR Publications Inc.

    Dr. JM Gamble

  38. Validated methods to identify patients with asthma–COPD overlap in healthcare databases: a systematic review protocol

    Article • BMJ Open, March 2019, BMJ

    Dr. JM Gamble

  39. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis

    Article • BMJ Open, January 2019, BMJ

    Dr. JM Gamble

  40. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes

    Article • Scientific Reports, October 2018, Springer Science + Business Media

    Dr. JM Gamble

  41. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink

    Article • BMJ Open, October 2018, BMJ

    Dr. JM Gamble

  42. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials

    Article • CMAJ Open, October 2018, Canadian Medical Association (CMA)

    Dr. JM Gamble

  43. Capsule Commentary on Franklin et al., Time to Filling of New Prescriptions for Chronic Disease Medications Among a Cohort of Elderly Patients in the USA

    Article • Journal of General Internal Medicine, September 2018, Springer Science + Business Media

    Dr. JM Gamble

  44. A systematic assessment of the availability and clinical drug information coverage of machine-readable clinical drug data sources for building knowledge translation products

    Article • Journal of the American Medical Informatics Association, July 2018, Oxford University Press (OUP)

    Dr. JM Gamble

  45. Measuring the impact of pharmacoepidemiologic research using altmetrics: A case study of a CNODES drug-safety article

    Article • Pharmacoepidemiology and Drug Safety, March 2018, Wiley

    Dr. JM Gamble

  46. Diabetes and the occurrence of infection in primary care: a matched cohort study

    Article • BMC Infectious Diseases, February 2018, Springer Science + Business Media

    Dr. JM Gamble

  47. The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study

    Article • Diabetes Research and Clinical Practice, February 2018, Elsevier

    Dr. JM Gamble

  48. The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin

    Article • Drugs - Real World Outcomes, September 2017, Springer Science + Business Media

    Dr. JM Gamble

  49. The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis

    Article • Iproceedings, September 2017, JMIR Publications Inc.

    Dr. JM Gamble

  50. The association between diabetes mellitus and incident infections: a systematic review and meta-analysis of observational studies

    Article • BMJ Open Diabetes Research & Care, May 2017, BMJ

    Dr. JM Gamble

  51. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study

    Article • The Lancet Diabetes & Endocrinology, November 2016, Elsevier

    Dr. JM Gamble

  52. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis

    Article • American Journal of Kidney Diseases, November 2016, Elsevier

    Dr. JM Gamble

  53. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial

    Article • Current Controlled Trials in Cardiovascular Medicine, October 2016, Springer Science + Business Media

    Dr. JM Gamble

  54. The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review and Meta-Analysis

    Article • JMIR mhealth and uhealth, September 2016, JMIR Publications Inc.

    Dr. JM Gamble

  55. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users

    Article • Medicine, June 2016, Wolters Kluwer Health

    Dr. JM Gamble

  56. Factors associated with early insulin initiation in Type 2 diabetes: a Canadian cross-sectional study

    Article • Diabetic Medicine, February 2016, Wiley

    Dr. JM Gamble

  57. Medical Practice Variations in Diabetes Mellitus

    Article • January 2016, Springer Science + Business Media

    Dr. JM Gamble

  58. Incretin-based medications for type 2 diabetes: an overview of reviews

    Article • Diabetes Obesity and Metabolism, April 2015, Wiley

    Dr. JM Gamble

  59. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review

    Article • BMJ Open, March 2015, BMJ

    Dr. JM Gamble

  60. Limited Impact of Drug Exposure Misclassification From Non-Benefit Thiazolidinedione Drug Use on Mortality and Hospitalizations From Saskatchewan, Canada: A Cohort Study

    Article • Clinical Therapeutics, March 2015, Elsevier

    Dr. JM Gamble

  61. Medication transitions and polypharmacy in older adults following acute care

    Article • Therapeutics and Clinical Risk Management, March 2014, Taylor & Francis

    Dr. JM Gamble, thoma marrie

  62. Changes in Thiazolidinedione Use and Outcomes Following Removal of a Prior-authorization Policy

    Article • Medical Care, January 2014, Wolters Kluwer Health

    Dr. JM Gamble

  63. Medical Practice Variations in Diabetes Mellitus

    Article • January 2014, Springer Science + Business Media

    Dr. JM Gamble

  64. Use Patterns of Antidiabetic Regimens by Patients with Type 2 Diabetes

    Article • Canadian Journal of Diabetes, December 2013, Elsevier

    Dr. JM Gamble

  65. Clinically Relevant Efficacy of Insulin Therapy in Patients with Type 2 Diabetes

    Article • Therapies, November 2013, Elsevier

    Dr. JM Gamble

  66. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study

    Article • Diabetes Obesity and Metabolism, July 2013, Wiley

    Dr. JM Gamble

  67. Evaluating the introduction of a computerized prior-authorization system on the completeness of drug exposure data

    Article • Pharmacoepidemiology and Drug Safety, March 2013, Wiley

    Dr. JM Gamble

  68. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study

    Article • Clinical Microbiology and Infection, March 2013, Elsevier

    Dr. JM Gamble

  69. Stress Hyperglycemia and Newly Diagnosed Diabetes in 2124 Patients Hospitalized with Pneumonia

    Article • The American Journal of Medicine, October 2012, Elsevier

    Dr. JM Gamble

  70. Restrictive Drug Coverage Policies can Induce Substantial Drug Exposure Misclassification in Pharmacoepidemiologic Studies

    Article • Clinical Therapeutics, June 2012, Elsevier

    Dr. JM Gamble

  71. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia

    Article • Respiratory Medicine, March 2012, Elsevier

    Dr. JM Gamble

  72. Quantifying the Impact of Drug Exposure Misclassification due to Restrictive Drug Coverage in Administrative Databases: A Simulation Cohort Study

    Article • Value in Health, January 2012, Elsevier

    Dr. JM Gamble

  73. Patient-Level Evaluation of Community-Based, Multifactorial Intervention to Prevent Diabetic Nephropathy in Northern Alberta, Canada

    Article • Journal of Primary Care & Community Health, November 2011, SAGE Publications

    Dr. JM Gamble

  74. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review

    Article • Canadian Medical Association Journal, October 2011, Canadian Medical Association (CMA)

    Dr. JM Gamble

  75. Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-Analysis

    Article • Journal of General Internal Medicine, June 2011, Springer Science + Business Media

    Thane Chambers, Dr. JM Gamble

  76. Patterns of Care and Outcomes Differ for Urban Versus Rural Patients With Newly Diagnosed Heart Failure, Even in a Universal Healthcare System

    Article • Circulation Heart Failure, March 2011, Wolters Kluwer Health

    Dr. JM Gamble

  77. Oxygen Saturations Less than 92% Are Associated with Major Adverse Events in Outpatients with Pneumonia: A Population-Based Cohort Study

    Article • Clinical Infectious Diseases, December 2010, Oxford University Press (OUP)

    Dr. JM Gamble

  78. Review: Statin use increases risk for diabetes

    Article • Annals of Internal Medicine, June 2010, American College of Physicians

    Dr. JM Gamble

  79. Admission Hypoglycemia and Increased Mortality in Patients Hospitalized with Pneumonia

    Article • The American Journal of Medicine, June 2010, Elsevier

    Dr. JM Gamble

  80. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study

    Article • Diabetes Obesity and Metabolism, January 2010, Wiley

    Dr. JM Gamble

  81. Dysglycaemia and 90 day and 1 year risks of death or readmission in patients hospitalised for community-acquired pneumonia

    Article • Diabetologia, November 2009, Springer Science + Business Media

    Dr. JM Gamble

  82. The Darkening Cloud of Diabetes: Do trends in cardiovascular risk management provide a silver lining?

    Article • Diabetes Care, October 2008, American Diabetes Association

    Dr. JM Gamble